Ethical issues in research with human volunteers: Preventive HIV Vaccine Trials MRC KZN AIDS Forum

27 November 2002

Catherine Slack: <u>slackca@nu.ac.za</u> HIV AIDS Vaccines Ethics Group University of Natal, Pietermaritzburg, KZN SOUTH AFRICAN AIDS VACCINE INITIATIVE

Aims & objectives

- To present ethical principles & requirements for health research with human volunteers
- To discuss their application to trials of preventive HIV vaccines in South Africa
- To create a discussion forum

SAAVI

- South African AIDS Vaccine Initiative (SAAVI):
 - To develop safe affordable and locally relevant HIV vaccines and to coordinate this process
- Main focus activities of SAAVI are:
 - Candidate vaccine development
 - Vaccine evaluation and immunology
 - Clinical trials
 - Education, human rights & mobilization
 - Ethics research and training

See SAJS (2000) Vol 96, 318 - 351

Clinical trials of HIV vaccines

- Pre-clinical tests: Is this vaccine safe? promising?
- <u>Phase 1</u>: Is this vaccine safe in humans? (18 months; smaller numbers of participants at lower risk of HIV)
- <u>Phase 2</u>: Does this vaccine produce the desired immune responses?

(24 months; larger numbers)

- <u>Phase 3</u>: Is this vaccine effective? Does it prevent HIV infection or disease progression ?
 (36 months +; with large numbers of participants at higher risk of HIV infection)
- Randomized, placebo controlled, double blinded

What is the role of ethics in research with human subjects?

- The objective of clinical research:
 - To develop generalizable knowledge to improve health and/ or increase the understanding of human biology
 - The aims of research are a recognized good, but research has the potential to treat participants as just "means to an end"
- The aim of ethics is:
 - To ensure that participants are treated with dignity and respect
 - While they contribute to the social good

What is the role of ethics in research? cont'd

- Ethics aims to:
 - Protect participants from harm
 - To promote their welfare
 - acts to restrain science
- However, ethics also promotes good science as participants who feel respected may:
 - Follow research requests
 - Answer truthfully
 - Return for follow up
 - Therefore increasing the quality of the data

What are the key principles in research ethics?

- NON-MALEFICENCE: "Do no harm":
 - There should be no intentional injury or harm to participants as a result of participation
- BENEFICENCE:
 - Minimize potential harms & maximize expected benefits of the research (Certain research bears no direct benefit for the participant, but benefits to society)
- RESPECT FOR AUTONOMY: "Self-rule":
 - Respect freedom of thought & action
 - Take special measures to protect the vulnerable or those with no capacity to choose

What are the key principles in research ethics cont'd?

- JUSTICE: Fair balance of risks and benefits
- Those who stand to benefit from research must contribute to its risks and discomforts
 - No group of persons should bear more than their fair share of the *burdens* of research; No group should be asked to bear research risks so that other groups enjoy benefits (knowledge/ products)
 - No group should be deprived of fair access to the benefits of research; No group should be unfairly excluded from research, as this denies them relevant knowledge/ health interventions

What makes research ethical?

The requirements for ethical research:

- 1 Social value
- 2 Scientific validity
- 3 Fair selection of participants
- 4 Favorable risk benefit ratio
- 5 Independent review
- 6 Adequate informed consent
- 7 Ongoing respect for dignity (confidentiality)
- 8 (Community participation)

Emanuel, Z, Wendler, D and Grady, C (2000) "What makes clinical research ethical?" JAMA, 283, 2701 – 2711

What makes research ethical? 1. Social value & 2. Validity

- 1. Social value: Society should gain important generalizable knowledge
- 2. Validity: Research must also be well designed and conducted
- Why? Research that is of no benefit to society or is poorly designed & conducted exposes subjects to risks and inconvenience for no purpose

What makes research ethical? 3. Fair choice of participants

- Participants should be chosen for participation fairly:
- 1) Selection should be based on scientific goals
 - not convenience or vulnerability
- Eligibility criteria for HIV vaccine trials
- Complexities:
 - Later efficacy trials of HIV vaccines, eligibility to participate includes *higher risk of HIV infection*
 - High risk may be linked to vulnerability; due to a range of factors (e.g. limited access to health care, socially stigmatized activities etc)

What makes research ethical? 3. Fair choice of participants

- Obligations of investigators:
 - To justify why vulnerable groups are involved; and what safeguards will be take to offset specified vulnerabilities
- 2) Individuals and commuities should be chosen so that burdens and benefits are fairly distributed:
 - The burdens of HIV vaccine research should be distributed fairly among various populations
 - Those who bear the burdens should access the benefits:
 - Early trials = knowledge; later trials = products
 - SAAVI: Access; negotiated price controls

- The potential risks to individual participants must be identified and minimized
- The potential benefits of the research must be identified and maximized
- The potential risks to individual subjects should be outweighed by the benefits to the individual or society
- "Favorable risk-benefit ratio"

- What are some of the potential risks of HIV vaccine trial participation?:
 - Physical side effects
 - False sense of security and possible increased risk behaviour
 - Trial related stigma
 - Exclusion from other HIV vaccine trials

Allen, M et al (2002). Trial related discrimination in HIV vaccine clinical trials. AIDS research and human retroviruses, 17, 667-674

- Vaccine induced sero-positivity:
 - It is hoped that candidate vaccines will induce an immune response in volunteers, including the production of antibodies against HIV
 - A "positive" response could be produced from a standard HIV test that only looks for antibodies against HIV. This will only happen if the test seeks antibodies for the same proteins found in the HIV vaccine
 - Potential for negative consequences

- What are risk minimization measures that should be undertaken?:
 - -Ongoing monitoring for effects
 - –Risk reduction counselling (optimal)
 - -Counselling around negative consequences (e.g. stigma) of disclosure
 - -Provision of support counselling

–Differential testing: antibody response and natural infection; ID card; psycho-legal support; advocacy

Grady, C (1994). HIV preventive vaccine research: Selected ethical issues. Jnl of Medicine & Philosophy, 19, 595 – 612;

Chesney, M et al., Strategies for addressing social & behavioural challenges in HIV vaccine trials. Jnl of Acquired Immune Deficiency Syndrome & Hum Retrovir 9, 30–35.

- What are expected benefits of HIV vaccine trials?:
 - Determining safety, immunogenicity, or efficacy of candidate HIV vaccines for South Africa
 - Access to counselling and interventions to reduce risk of HIV infection
 - Access to medical monitoring and care

- The potential risks to individual subjects should be outweighed by the benefits to the individual or society:
- Who decides this?
 - Research ethics committees at every participating institution
 - Participating communities via establishment of representative participatory structures
 - Each and every individual via informed consent

Debate: Minimizing risk of HIV infection

- What complexities exist in phase III efficacy trials for risk reduction?:
 - Phase III trials aim to assess if vaccines can prevent HIV infection, by comparing rates of infection in vaccinated and non-vaccinated groups
 - Determinations of efficacy rest on the exposure of a proportion of participants to HIV
 - Simultaneously, researchers have to minimize potential harms and provide participants with risk reduction counselling. This should be optimal
 - Potential conflict of interest?

Ijsselmuiden, CB (1995) Ethical aspects of HIV vaccine research. AIDS Bulletin, 4, 13-16

Debate: Maximizing benefits: Access to treatment

 In all phases of HIV vaccine trials some participants may become infected with HIV, despite risk reduction measures:

Ensuring access to treatment:

-Are investigators and sponsors obligated to ensure access to treatment for volunteers who become HIV infected?

-At what level e.g. access to Antiretroviral Treatment (ART) ?

Guenter, Esparza & Macklin (2000). Ethical considerations in international HIV vaccine trials: Summary of a consultative process conducted by UNAIDS. Jnl of Medical Ethics, 26, 37-43,

Debate: Maximizing benefits: Access to treatment cont'd

Arguments:

- Potential for distorted belief in efficacy of the experimental vaccine ("therapeutic misconception") false sense of security & "behavioural disinhibition"
- Favourable balance of risks and benefits
- Justice considerations: Equity for participants from sponsor and host countries; obligations to proactively reduce inequities in health care

Schüklenk, U. (2000). Protecting the vulnerable: testing times for clinical research ethics. Social Science and Medicine, 51, 969-977. Schuklenk U, Ashcroft RE. International Research Ethics. *Bioethics* 2000; 14: 158-172; Reider Lie (1998). Ethical issues in clinical trial collaborations with developing countries with special reference to preventive HIV vaccine trials with secondary endpoints. <u>http://www.ethica.uib.no/who.pdf</u>; Harris, J (1998) 'Ethical Implications of Phase III Clinical Trials of HIV Vaccines: Justice issues : burdens, benefits and availability' Working Paper for UNAIDS. Geneva: UNAIDS

Debate: Maximizing benefits: Access to treatment cont'd

Best proven or "highest attainable"

Considerations

- -Undue inducement
- -Research related inequities in health care

Benatar, S & Singer, P. (2001). A new look at international research ethics. *BMJ*, 321, 824-826.
London, AJ. (2001). Equipoise and international human subjects research. *Bioethics*, 15 (4), 313-332. Also Bloom, B (1998) The highest attainable standard: Ethical issues in AIDS vaccines. Science, 297, 186-188

What makes research ethical? 5. Independent review

- Researchers operate at the interface of multiple obligations and interests:
 - Undertake research, acquire funding, further careers, protect human subjects
 - Can potentially bias how researchers perceive their research designs and conduct research
 - Therefore review by committee "at arms length"
 - To ensure that participants are protected and welfare promoted (1, 2, 3, 4, 6, 7)

- Informed consent:
 - The right to choose freely whether or not to participate based on an understanding of all relevant information
 - Ensures that participants will only take part if the research is consistent with their interests, values and preferences (autonomy)
 - See Emmanuel, Z, Wendler, D and Grady, C (2000) "What makes clinical research ethical?" JAMA, 283, 2701 – 2711

Components:

- 1 Disclosure of information
- 2 Comprehension or understanding
- 3 Voluntariness or freedom
- 4 Capacity to consent
- 5 Explicit formal consent

In HIV vaccine trials, consent is also staged:

- Screening
- Enrollment
- HIV testing

• 1 Information

- Participants must be informed of the following:
 - Aims, duration
 - Methods (e.g. randomization, placebo, blinding)
 - Practical aspects (VCT, tests, visits etc)
 - Potential risks (e.g. trial related stigma)
 - Expected benefits (e.g. counselling)
 - Right to withdraw
 - Confidentiality (and limits if any)
 - Personal implications

- What complexities exist?
 - Transmission of complex information, compounded by language differences, translation
 - Information transmission typically viewed as a one way process
 - Determinations of "what" must be transmitted?

See Lindegger, G & Richter, L (2000) HIV vaccine trials: Critical issues in informed consent. SAJS, 96, 313-318

- 2 <u>Comprehension</u>
 - Disclosure is not sufficient
 - Understanding must be ensured and tested
- What complexities exist?
 - Social desirability: Tendency to act to avoid disapproval - impacts on reported understanding
 - Over-emphasis on understanding of technical aspects (e.g. placebo)
 - Understanding of personal implications ?
 - "Tests of understanding": May emphasize technical aspects, may rely on ST memory

- Researchers and counsellors can enhance comprehension by:
 - Creating an optimal environment for decision making ("consent counselling")
 - Ensuring use of counsellors with "values match" to potential participants
 - Encouraging dialogue; discussion with family
 - Allowing time to reflect
 - Sensitivity to process aspects of counselling (e.g. social desirability, non-verbal cues)
 - Multiple methods of assessing comprehension

- 3 <u>Voluntariness</u>
- Participants must be free to choose whether or not to participate:
 - Free of coercion (threat of negative sanction)
 - Undue influence (incentives that are so large that cause prospective participants:
 - To expose themselves to risks they would otherwise consider unacceptable; or
 - To ignore or devalue concerns about risks
- Complexities? Vulnerability of potential participants

- Researchers can promote participant's freedom by:
 - Adequate assessment of specific vulnerability factors
 - Commitment to offsetting these, e.g.
 - Education to offset lack of familiarity with research
 - Avoiding excessive payment to offset impoverishment
 - Providing participants with ways to voice concerns and monitor the impact of participation
 - CABs; trial site counsellors

Debate: Informed consent & culture

 Is it appropriate to secure first person informed consent (IC) in some cultural contexts?

–Can legitimate parties (husbands/ traditional leaders) give proxy consent?

- First person IC = best safeguard against exploitation
 Therefore substantive principle must apply
- Demonstrate respect for multi-person involvement
 - -In procedural implementation of consent

Endorsement of community leader to enter community;

•Respect participant's choice to involve others Ijsselumuiden, C & Faden, R (1992). Research and informed consent in Africa: Another Iook. N Engl Jnl Med, 326, 830-834, Also Lindegger & Richter (2000) SAJS, 96, 313-8

What makes research ethical? 7. Respect for dignity

 Once enrolled, researchers should respect the dignity of participants in an ongoing manner by:

–Respecting their right to withdraw at any time (consent is "revocable")

-Monitoring their welfare throughout the research (ongoing "social harm" monitoring)

–Informing volunteers of research results

-Respecting confidentiality of freely volunteered data Allen, M et al (2002). Trial related discrimination in HIV vaccine clinical trials. AIDS research and human retroviruses, 17, 667-674

What makes research ethical? 8. Community participation

- Why community participation?
 - Right and responsibility to participate in HIV vaccine development activities
 - Can offset potential vulnerabilities
- What are the mechanisms?
 - Include the formation of a Community Advisory Board (CAB)
- What possible roles?
 - Includes inputs to design (e.g. IC)
 - Advising on cultural conventions, expectations;
 - Evaluating impact of the research

Community participation cont'd

- What are the benefits of community participation?
 - Enhanced cultural appropriateness
 - Increased acceptability of the research to the participating community
 - Fairness regarding important decisions (e.g. adequate incentives)
 - Sound bi-directional information exchange
- In preparation for HIV vaccine trials in South Africa community structures are being formed at sites

Community participation cont'd

- What are the complexities?
 - Defining community: which stakeholders and interest groups must be represented?
 - Difficulties in ensuring representation of such groups
 - Defining "participation" (Recipients of education full and equal partners)
 - Determining what "participation point" on the research continuum? (Protocol development dissemination of results)

Summary: Ethical issues in HIV vaccine research

- The ethical considerations in HIV vaccine research apply to other research with human subjects, especially:
 - International collaborative research
 - HIV prevention research
 - Research with potentially vulnerable participants
- Complex risk-benefit determinations & potentially vulnerable participants require careful review, involved comunities and sound consent procedures

HIV AIDS Vaccines Ethics Group

- To raise awareness and build the ethical capacity of various stakeholders
- To research ethical aspects of clinical trials, with specific attention to informed consent
- To co-ordinate the development of ethical guidelines in collaboration with national ethics structures
- To examine behavioural aspects of HIV vaccine trials
- To support ethical trials in Africa through the African AIDS Vaccine Program

Contact details

HIV AIDS Vaccine Ethics Group <u>Haveg@nu.ac.za</u>

School of Psychology University of Natal, Private Bag X01 Scottsville 3209 Ph: + 27 33 260 6166 Fax: + 27 33 60 6167 PI: Prof G Lindegger: lindegger@nu.ac.za Co-ordinator: C Slack: slackca@nu.ac.za

HAVEG@nu.ac.za: 2002